MetaCap

Schrodinger Inc. (SDGR)

NASDAQ: SDGRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

22.93-3.41 (-12.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SDGR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.79
52-week range
10.95 – 34.00
Day range
22.75 – 26.30
Volume / Avg
1.88M / 2.08M
Beta
—

52-week range

$10.95$34.00

SDGR stock today

On Nov 20, SDGR ended the session at $22.93, shedding $3.41 (12.95%), versus the S&P 500's 3.70% decline. At this level, SDGR sits in the middle of its 52-week range of $10.95 to $34.00: 32.6% below the high, set on Nov 11, 2026 and 109.5% above the low. SDGR is up 28.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 39.2%.

Schrodinger has posted a net loss over the last twelve months (EPS of -$0.79), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Schrodinger

Company profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Ramy Farid Ph.D.
Headquarters
New York, NY
Employees
850
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Schrodinger generated $255.9 million in revenue, up 23.3% from fiscal 2024. Schrodinger reported a net loss of $103.3 million, compared with a loss of $187.1 million a year earlier. Gross margin was 55.7% (down from 63.6%) and operating margin -65.2%.

Schrodinger annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$255.87M$207.54M$216.67M$180.96M$137.93M
Growth+23.29%-4.21%+19.73%+31.19%+27.60%
Net income$-103.27M$-187.12M$40.72M$-149.19M$-100.39M
EPS (diluted)$-1.41$-2.57$0.54$-2.10$-1.42

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$33.57+46.40%

  • Strong buy 0
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $29.00High $37.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.50 vs $-0.66
Surprise
+24.24%

SDGR news

All SDGR news

Schrodinger peers

Health Care sector
SDGR peer companies
CompanyPrice% ChgMarket capCompare
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs SDGR
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs SDGR
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs SDGR
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs SDGR
RAREUltragenyx Pharmaceutical Inc.16.48-4.30%$1.68Bvs SDGR
BRVEBraveheart Bio Inc.20.39+5.81%$1.67Bvs SDGR
AGIOAgios Pharmaceuticals Inc.27.60-4.03%$1.65Bvs SDGR
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs SDGR

Indexes, lists and sector

Schrodinger stock FAQ

What is Schrodinger's stock price today?

SDGR last traded at $22.93 as of Nov 20, 4:00 PM EST, down 12.95% on the day. Prices are delayed at least 15 minutes.

Who is Schrodinger's CEO?

Dr. Ramy Farid Ph.D. is the chief executive officer of Schrodinger Inc., which has about 850 employees.

What is the SDGR 52-week high?

The 52-week high for SDGR is $34.00 and the 52-week low is $10.95. The stock is currently 32.6% below its high.

Compare SDGR